 Recombinant human beta analogue regulator hematopoiesis patients chemotherapy urogenital cancers patients advanced urologic cancers courses chemotherapy trial Fifty units recombinant human beta analogue Otsuka Pharmaceutical Tokyo Japan severe neutropenia consecutive days patients first course chemotherapy control second course durations leukocytopenia second course first course patients Recovery neutrophil number number second course hematopoietic activities single double injection numbers eosinophilic basophilic granulocytes monocytes platelets Adverse effects injections high fever chills indomethacin